StockData
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31

NEOGEN CORP

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026
$11.63−0.18 (-1.52%)

Close on Oct 19, 2026

Market cap
$2.54B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Jan 7, 2027, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q1 FY2027
Ended Aug 31, 2026
Oct 6, 2026After market close$222.80M$-0.05$0.08
Q4 FY2026
Ended May 31, 2026
Jul 30, 2026Before market open$225.30M$-0.05$0.09
Q3 FY2026
Ended Feb 28, 2026
Apr 9, 2026Before market open$211.20M$-0.08$0.09
Q2 FY2026
Ended Nov 30, 2025
Jan 8, 2026Before market open$224.70M$-0.07$0.10
Q1 FY2026
Ended Aug 31, 2025
Oct 9, 2025Before market open$209.20M$0.17$0.04
Q4 FY2025
Ended May 31, 2025
Jul 29, 2025Before market open$225.50M$-2.82$0.05
Q3 FY2025
Ended Feb 28, 2025
Apr 9, 2025Before market open$221.00M$-0.05$0.10
Q2 FY2025
Ended Nov 30, 2024
Jan 10, 2025Before market open$231.30M$-2.10$0.11
Q1 FY2025
Ended Aug 31, 2024
Oct 10, 2024Before market open$217.00M$-0.06$0.07
Q4 FY2024
Ended May 31, 2024
Jul 30, 2024Before market open$236.80M$-0.02$0.10
Q3 FY2024
Ended Feb 29, 2024
Apr 9, 2024Before market open$228.80M$-0.01$0.12

Company guidance

Outlook given with results on Oct 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted EBITDAnon-GAAPfiscal year 2027$181.00M to $183.00MRaised
total revenuefiscal year 2027$885.00M to $890.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Neogen filed with the SEC